United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McCormick

Three companies falling on earnings, and three sets of reasons why.

3M, McCormick, and Pfizer

Pfizer's (PFE) CEO Albert Bourla on Q4 2019 Results - Earnings Call Transcript

Apple

General Electric

Apple, General Electric, Pfizer and MMM were our top stock trades for Wednesday. That said, here's a look at the charts for the stocks.

4 Top Stock Trades for Wednesday: Apple, General Electric, 3M & PFE

The impact of generic competition for Lyrica was expected, but investors saw other things in the quarterly report that concerned them.

Pfizer's Q4 Results, 2020 Guidance Leave Investors Cold

The big drugmaker provided a disappointing Q4 update.

Why Pfizer's Shares Sank Today

Pfizer (PFE) earnings for the pharmaceutical company's fourth quarter of 2019 have PFE stock falling hard Tuesday on an EPS miss.
The post Pfizer Earnings: PFE Stock Slips 5% on Q4 Miss appeared first on InvestorPlace.

Pfizer Earnings: PFE Stock Slips 5% on Q4 Miss

Pfizer Inc  on Tuesday reported lower-than-expected quarterly profit and a decline in revenue as sales of its off-patent pain treatment Lyrica more than halved, sending its shares down more than 3%.

Pfizer profit misses estimates, revenue declines as Lyrica sales tumble

When Pfizer Inc. (NYSE: PFE) released its fourth-quarter earnings report before the opening bell Tuesday, the pharmaceutical giant said that it had $0.55 in earnings per share (EPS) and $12.7 billion in revenue.

How Far Will Pfizer Stock Slump?

The 3 Most Important Things to Know About Pfizer's Q4 Earnings Results

Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.

Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down

Pfizer reported another mediocre quarter on Tuesday morning, raising the odds that the stock will resume a 13-month downtrend.

Pfizer Stock Could Test 2019 Low

Pfizer Inc  posted a quarterly profit on Tuesday that came in below Wall Street estimates, as sales of breast cancer drug Ibrance fell short of expectations.

Pfizer profit misses as breast cancer drug sales fall short of estimates

Pfizer (NYSE: PFE) reported adjusted fourth-quarterly earnings of 55 cents per share on Tuesday, which missed the analyst consensus estimate of 57 cents by 3.51%.

Pfizer Reports Mixed Q4 Earnings

Pfizer is slated to release its Q4 and full-year 2019 results on January 28, 2020. For full year 2019, Trefis estimates that the company will report: Revenues of $52.2 billion, reflecting 2.8% y-o-y decline, primarily driven by the company’s consumer healthcare segment spin off.

What To Expect From Pfizer’s Q4?

Pfizer earnings and sales both missed expectations for the Dow Jones pharmaceuticals company. Pfizer stock fell early Tuesday.

Pfizer Earnings, Sales Miss; Dow Jones Drug Giant Falls

Shares of Pfizer Inc. PFE, +0.85% fell 0.9% in premarket trading Tuesday, after the drug maker reported a fourth-quarter profit that missed expectations, while revenue rose in line with forecasts.

Pfizer's stock falls after profit misses expectations, while revenue was in line

Pfizer reported a 9% drop in fourth-quarter revenue, hurt by intense competition for its pain treatment Lyrica that lost patent protection last year.

Pfizer posts 9% fall in fourth-quarter revenue

Pfizer (NYSE: PFE) announces its next round of earnings this Tuesday, January 28.

A Preview Of Pfizer's Q4 Earnings

Allergan

Biogen

This is already a huge week for earnings, as nearly half of the Dow Jones industrial average is reporting, and roughly 150 companies in the S&P 500 as well.

What to Expect From Pfizer, Biogen and Allergan Earnings Tuesday Morning

Exxon Mobil

Nearly half of the 30 Dow Jones industrial average components are scheduled to post their latest quarterly reports this week — 14 in total.

Half the Dow Reports This Week: Apple, Exxon, Pfizer and More

Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to  have made up for lower sales in the Upjohn group.

Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?

Pfizer's U.S. generic drug subsidiary, Greenstone, is partnering with men's health provider Roman to provide Viagra to patients.

Pfizer to Market Viagra Through Roman's Telehealth Service

Lam Research

QUALCOMM

Three large-cap stocks that should surprise when they announce earnings over the coming weeks.

Three Stocks That Could Surprise During Earnings Season

While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.

News for Pfizer Stock (PFE)